002603 以岭药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.65212.129-6.68612.08523.626
总资产报酬率 ROA (%)2.9369.532-4.7838.11816.158
投入资产回报率 ROIC (%)3.49611.634-5.8689.83219.722

边际利润分析
销售毛利率 (%)60.05464.27750.18757.28263.771
营业利润率 (%)20.48320.732-10.57817.24922.577
息税前利润/营业总收入 (%)20.12020.307-11.94216.57822.346
净利润/营业总收入 (%)16.74816.368-11.27313.02818.813

收益指标分析
经营活动净收益/利润总额(%)101.779105.62879.28094.947103.068
价值变动净收益/利润总额(%)1.0630.377-4.9753.8770.414
营业外收支净额/利润总额(%)-2.176-1.99913.909-5.677-1.759

偿债能力分析
流动比率 (X)2.5022.3581.6631.4721.496
速动比率 (X)1.9211.6840.9930.9191.079
资产负债率 (%)19.65819.69423.40332.63633.111
带息债务/全部投入资本 (%)0.738-0.387-0.44314.73316.356
股东权益/带息债务 (%)12,908.334-24,813.824-21,591.475554.734495.085
股东权益/负债合计 (%)408.976408.046327.983206.624202.053
利息保障倍数 (X)275.627-1,127.566-34.69964.873140.593

营运能力分析
应收账款周转天数 (天)46.61356.414100.23372.01247.934
存货周转天数 (天)130.820208.153233.312182.969146.462